News >

New Developments Propel Biosimilar Penetration of US Oncology Market

Gina Columbus @ginacolumbusonc
Published: Friday, Aug 23, 2019

The biosimilars realm of oncology has been surrounded by a burst of clinical and regulatory news this week, with the read out of phase III findings and extension data, legality issues, and more.  

 

References

  1. Esteva FJ, Baranau YV, Baryash V, et al. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial [published online ahead of print August 19, 2019]. Cancer Chemo and Pharma. doi: 10.1007/s00280-019-03920-4.
  2. Celltrion and Teva announce FDA approval of Herzuma (trastuzumab-pkrb), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast cancer for certain indications [news release]. Incheon, South Korea, and Jerusalem, Israel: Celltrion. Published December 14, 2018. https://bit.ly/2KY6s8i. Accessed December 17, 2018.
  3. Esteva FJ, Lee S, Yu S, et al. 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Lancet Oncol. 2017;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5.
  4. Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab). Amgen. Published August 22, 2019. https://bit.ly/2L0pACF. Accessed August 22, 2019.
  5. McBride H, Maher G, Sweet H, Foltz I, Kuhns S. Functional similarity of proposed biosimilar ABP 798 with rituximab. Blood. 2017;130:5001. bloodjournal.org/content/130/Suppl_1/5001.
  6. United States Court of Appeals for the Federal Circuit. Genentech, Inc., Plaintiff-Appellant City of Hope, Plaintiff v. Immunex Rhode Island Corporation, Amgen Inc., Defendants-Appellees. Published August 16, 2019. https://bit.ly/2zh99wo. Accessed August 22, 2019.
  7. UnitedHealthcare. Network bulletin. Published August 2019. https://bit.ly/2KQCZhO. Accessed August 22, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x